title: Susceptibility genes and pharmacogenetics in ocular inflammatory disorders.
abstract: Ocular inflammatory disorders encompass uveitis, scleritis, keratitis, and other ocular diseases where inflammation may play a role. Although age-related macular degeneration (AMD) is clinically characterized by degenerative changes in the macula, accumulating evidence suggests that inflammation plays an important role in its pathogenesis. Pharmacogenetics is the study of the influence of genetic variation and its effects on drug efficacy or toxicity. There are no pharmacogenetic studies in uveitis and very few in AMD therapies. In this review, the authors describe the susceptibility genes related to uveitis and AMD and the important advances in pharmacogenetic research in relation to AMD and uveitis therapy. They propose polygenic and composite models of treatment responses to fulfill individualized drug therapy in intraocular inflammatory disorders.
authors.affiliation: Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
authors.forename: Baoying
authors.initials: B
authors.lastname: Liu
authors.forename: H Nida
authors.initials: HN
authors.lastname: Sen
authors.forename: Robert
authors.initials: R
authors.lastname: Nussenblatt
mesh_terms: D000963:Antimetabolites / Q000627:therapeutic use; D001688:Biological Products / Q000627:therapeutic use; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D011110:Polymorphism, Genetic; D011965:Receptors, Glucocorticoid / Q000235:genetics; D014605:Uveitis / Q000188:drug therapy* / Q000235:genetics*
chemical_list: D000963:Antimetabolites; D001688:Biological Products; D011965:Receptors, Glucocorticoid